Skip to Main Content

Paper Details

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Eur J Cancer
14
2019
Bev, ET, Hypertension, Leukemia Group B 40503, OS, PATIENTS, bevacizumab, hormone receptor-positive metastatic breast cancer, hypertension, liver events, metastatic breast cancer, patients, proteinuria
Author NameAffiliation
Terry HyslopDuke University
Lisa A CareyUniversity of North Carolina
Eric P Winer
Clifford A HudisAmerican Society of Clinical Oncology (ASCO)
  • 1 - 4

Datasets

Release 1.2